Begin main content

dupilumab

Last Updated: November 14, 2019
Result type: Reports
Project Number: SR0636-000
Product Line: Common Drug Review

Generic Name: dupilumab

Brand Name: Dupixent

Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.

Indications: atopic dermatitis

Manufacturer Requested Reimbursement Criteria1: For the treatment of patients aged 12 years and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable and/or who are refractory to or ineligible for systemic immunosuppressant therapies (i.e., due to contraindications, intolerance, or need for long-term treatment).

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule B

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input postedSeptember 23, 2019
Patient group input closedNovember 12, 2019
Clarification:

- Patient input submission received from Eczema Society of Canada

Patient input summary sent for review to patient input groups-
Patient group comments on input summary closed-
Submission receivedOctober 22, 2019
Submission accepted for reviewNovember 05, 2019
Review initiatedNovember 06, 2019
Draft CADTH review report(s) sent to sponsorJanuary 27, 2020
Comments from sponsor on draft CADTH review report(s) receivedFebruary 05, 2020
CADTH review team's comments on draft CADTH review report(s) sent to sponsorMarch 06, 2020
Canadian Drug Expert Committee (CDEC) meetingMarch 18, 2020
CDEC recommendation sent to sponsor and drug plansMarch 30, 2020
To
April 01, 2020